

Title: Chemotherapy Significantly Improves Long-term Survival of Small Lesion Node Negative Metaplastic Breast Carcinoma in T1c population Rather than T1a and T1b

Authors

Qitong Chen¹, Qin Zhou¹, Hongye He¹, Yeqing He¹, Yunchang Yuan², Qiongyan Zou^{1,*}, Wenjun Yi^{1,*}

Affiliation(s):

1. Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, 410000, Hunan, China;
2. Department of Thoracic Surgery, The Second Xiangya Hospital, Central South University, Changsha, 410000, Hunan, China.

Corresponding Authors:

Prof Qiongyan Zou, zqy4311@csu.edu.cn;
Prof Wenjun Yi, yjwenjun@csu.edu.cn.


Supplementary table 1. Characteristics of female patients diagnosed with primary MpBC in SEER database

Characteristics	Before PSM, n (%)			<i>P</i> -value ^a
	Overall	Chemotherapy	Chemotherapy-naïve/Unknown	
Sample size	890	404	486	
Age				
≤45	92 (10.3)	62 (15.3)	30 (6.2)	<0.001
46-65	404 (45.4)	239 (59.2)	165 (34.0)	
>65	394 (44.3)	103 (25.5)	291 (59.9)	
Marriage				
Married	493 (55.4)	249 (61.6)	244 (50.2)	<0.001
Single	95 (10.7)	54 (13.4)	41 (8.4)	
DSW	250 (28.1)	80 (19.8)	170 (35.0)	
Unknown	52 (5.8)	21 (5.2)	31 (6.4)	
Race				
White	709 (79.7)	310 (76.7)	399 (82.1)	0.058
Black	121 (13.6)	66 (16.3)	55 (11.3)	
Other	51 (5.7)	26 (6.4)	25 (5.1)	
Unknown	9 (1.0)	2 (0.5)	7 (1.4)	
Median household income				
<\$50000	230 (25.8)	92 (22.8)	138 (28.4)	0.159
\$50000~70000	472 (53.0)	222 (55.0)	250 (51.4)	
>\$70000	188 (21.1)	90 (22.3)	98 (20.2)	
Year				
2000-2003	151 (17.0)	53 (13.1)	98 (20.2)	<0.001
2004-2008	249 (28.0)	99 (24.5)	150 (30.9)	
2009-2012	235 (26.4)	113 (28.0)	122 (25.1)	
2013-2016	255 (28.7)	139 (34.4)	116 (23.9)	
Grade				
I-II	275 (30.9)	74 (18.3)	201 (41.4)	<0.001
III-IV	480 (53.9)	285 (70.5)	195 (40.1)	
Unknown	135 (15.2)	45 (11.1)	90 (18.5)	
T stage				
T1a	49 (5.5)	11 (2.7)	38 (7.8)	<0.001
T1b	166 (18.7)	47 (11.6)	119 (24.5)	
T1c	675 (75.8)	346 (85.6)	329 (67.7)	
ER				
Positive	163 (18.3)	68 (16.8)	95 (19.5)	<0.001
Negative	645 (72.5)	323 (80.0)	322 (66.3)	
Unknown	82 (9.2)	13 (3.2)	69 (14.2)	
PR				
Positive	130 (14.6)	55 (13.6)	75 (15.4)	<0.001

Negative	674 (75.7)	333 (82.4)	341 (70.2)	
Unknown	86 (9.7)	16 (4.0)	70 (14.4)	
HER2				
Positive	24 (2.7)	19 (4.7)	5 (1.0)	<0.001
Negative	392 (44.0)	200 (49.5)	192 (39.5)	
Unknown	36 (4.0)	11 (2.7)	25 (5.1)	
Unavailable	438 (49.2)	174 (43.1)	264 (54.3)	
Molecular Subtype				
HR+ /HER2-	115 (12.9)	53 (13.1)	62 (12.8)	<0.001
HER2 enriched	24 (2.7)	19 (4.7)	5 (1.0)	
TNBC	273 (30.7)	145 (35.9)	128 (26.3)	
Unknown	478 (53.7)	187 (46.3)	291 (59.9)	
Surgery				
Non-surgery	16 (1.8)	3 (0.7)	13 (2.7)	0.057
Surgery	874 (98.2)	401 (99.3)	473 (97.3)	
Radiation				
Radiation	441 (49.6)	230 (56.9)	211 (43.4)	<0.001
Non-radiation/Unknown	449 (50.4)	174 (43.1)	275 (56.6)	

^a*P*-value from Pearson's chi-square test of independence.

Abbreviations: DSW, divorced/separated/widowed; ER, estrogen receptor; HER2, human epidermal growth receptor 2; HR, hormone receptor; MpBC, Metaplastic breast carcinoma; OS, overall survival; PR progesterone receptor; PSM, propensity score match; TNBC, triple-negative breast cancer.



Supplementary Figure 1 Kaplan–Meier curves comparing survival of patients with MpBC based on chemotherapy and chemotherapy-naïve/unknown for overall survival (OS) and breast cancer-specific survival (BCSS). **(A) (B)** Survival analysis of OS before and after propensity score matching (PSM); **(C) (D)** Survival analysis of BCSS in the T1b stage subgroup